Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib With or Without Chemotherapy for Recurrent/Metastatic Osteosarcoma
ChiCTR-OPC-17010758Phase 4Recruiting
- Sponsor
- Xijing Hospital
- Start
- Mar 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in osteosarcoma (OS) (2 arms), sponsored by Xijing Hospital. Primary endpoints: progression-free survival, objective response rate and 3 more. Started Mar 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR-OPC-17010758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17010758.